Neurology

Therapies for neurological conditions including epilepsy, multiple sclerosis, ALS, and neuromuscular diseases.

Companies

Pipeline Drugs

2142

Key People

2349

Neurology Pipeline (2142 drugs)

Commercial: 327Preclinical: 225Pre-clinical: 196Approved: 175Phase 2: 132Phase 3: 99Development: 92Phase 1: 88Research: 46Discovery: 44Phase 1/2: 43Marketed: 37Phase 2/3: 24Discovery/Preclinical: 23Not Specified: 18Unknown: 18Phase 2b: 11Research/Development: 11Development/Commercial: 11Early-stage Clinical: 11Launched: 10Not Disclosed: 9Approved/Commercial: 9Development/Validation: 9Clinical Development: 8FDA Cleared: 7Clinical: 6Clinical Trial: 6Regulatory Review: 6Phase III: 6Pre-Clinical: 6Research/Pre-clinical: 6Commercial/Development: 6Not Specified (Typically Phase 2-3): 6In Development: 6Commercial Launch: 5Pivotal Trial: 5Preclinical/Phase 1: 5Pre-clinical Tool: 5Phase 1b/2a: 5Phase II: 5Clinical-stage: 5Discovery/Pre-clinical: 5Pre-clinical/Clinical: 5Service: 5Marketed (Global): 5Pre‑clinical: 4Under Development: 4Various: 4Clinical Expansion: 4Not Applicable (Service): 4Undisclosed: 4Pre-clinical/Development: 4Clinical Evidence Generation: 4N/A: 4Clinical Research: 3Partnership Development: 3R&D: 3All Phases: 3Clinical Service: 3Platform / Asset: 3Phase I/II: 3Investigational: 3Clinical Investigation: 3Phase 1/2a: 3Planned: 3Not Disclosed (Sponsor-led): 3Early Clinical: 3Phase 2b/3: 3Phase 1b: 3Commercial/Service: 3Research & Development: 3Registration: 3Phase 4: 3Research/Pre‑clinical: 3Human Clinical: 3preclinical: 2Discovery/Development: 2Clinical Validation: 2Continuous Development: 2Development/Regulatory: 2Research/Preclinical: 2Regulatory Filing: 2Phase IIb/III: 2Early Feasibility Study: 2Pre-clinical/Validation: 2Various (Typically Phase 2-4): 2Approved (KZ) / Pre-market (US): 2Pilot: 2Pre-IND: 2Pre-clinical/Research: 2Assay Development: 2NDA Submitted: 2Pre-clinical/Phase 1: 2Development/Commercializing: 2Pivotal: 2Pre-clinical / Exploratory: 2ANDA Filed/Development: 2Pre-clinical/Exploratory: 2Clinical Feasibility: 2Commercialization: 2Commercial / Development: 2Late-stage Development: 2Preclinical/Research: 2Regulatory Approved: 2Phase I: 2Phase II/III: 2FDA Approved: 2IND-Enabling: 2Pre-market (NMPA under review): 2Clinical Trials: 2Filed: 1PMA Supplement: 1Development & Validation: 1Development & Expansion: 1Assay Menu Expansion: 1Integrated Solution: 1Solution: 1Preclinical/Early Clinical: 1Post-approval study: 1Not Disclosed (Likely Preclinical/Early Clinical): 1Phase 1/2A: 1Development/Commercial (LDT): 1Cleared: 1Validation: 1Implementation: 1Commercial Tool: 1Service Offering: 1N/A (Diagnostic): 1Phase IIb: 1Pilot/Phase 2: 1Screening/Diagnostic: 1Various (Typically Phase 3): 1Under Review: 1Research Use Only: 1Not Disclosed (Likely Pre-clinical): 1Research & Regulated Studies: 1Development / Pilot: 1Commercial (ex-US) / Pre-market (US): 1Proposed Acquisition: 1Pre-clinical or Undisclosed: 1Phase 1-3: 1Early Commercialization: 1Development/ANDA Submission: 1Development to Commercial: 1Strategic Development: 1Research Use Only (RUO): 1Beta/Commercial Launch: 1Pre-commercial: 1Development/Acquisition: 1Phase 2b (Planned): 1ANDA Filed/Pre-approval: 1Expanded Access: 1First-in-Human / Clinical: 1Pivotal Trial Planned: 1Phase 2/Phase 3: 1Ongoing: 1Clinical Studies: 1Pre-clinical / Phase 1 (BA/BE): 1Feasibility Study: 1Phase 2a PoC: 1Not Applicable (Service Provider): 1Commercial (RUO): 1Late Stage (assumed Phase 3-ready): 1Available Now: 1Facility Development & Licensing: 1Development/Prototype: 1Prototype: 1Pre-clinical / Phase 1 (implied): 1Not Applicable (Device): 1Work in Progress: 1Pivotal Clinical Trial: 1Commercial (Components awaiting regulatory clearance): 1IND enabling: 1AI Discovery: 1Phase 3 / Registration: 1Commercial / Line Extension: 1Discovery/Validation: 1Commercial (EU); Investigational (US): 1Pivotal BA/BE: 1First-in-Human: 1Post-Market: 1Phase 3 (Pivotal Study): 1Pilot Trial: 1Platform Development: 1Pre-clinical/Feasibility: 1Development/Pre-clinical: 1Pilot Validation: 1N/A (Interventional Trial): 1Not specified: 1Not Specified (Orphan Designated): 1Development & Clinical Research: 1Approved/Expanded Access: 1Proof-of-Principle: 1Phase IIa: 1Lead Optimization: 1Phase 2 Planned: 1Clinical Evaluation: 1NDA Submission: 1ANDA Submission: 1Business Development: 1Market Launch: 1Phase Ib/II: 1Various (Pre-clinical to Clinical): 1Clinical Trials / Pilot Studies: 1Clinical Trial Initiated: 1Preclinical/Proof-of-Concept: 1Clinical Validation / Regulatory: 1Preclinical/Discovery: 1Preclinical/IND-enabling: 1IND-enabling: 1Commercial Expansion: 1IND ready: 1ANDA Development / Commercial: 1Phase I-IV: 1Development/Testing: 1Regulatory: 1Research/Discovery: 1Phase 2 (planning): 1Phase 1-2: 1Pre-clinical/Clinical Development: 1Licensed/Orphan Designation: 1Phase 2/Spin-out: 1Not Specified (Acquired Pipeline): 1Phase 1/2 (not specified): 1Pivotal Trial (Planned): 1Applied Research/Service: 1Varies by Sponsor Protocol: 1Research/Clinical Study: 1Pivotal Trial Completed: 1Clinical Stage: 1Commercial / Lifecycle Management: 1Phase 2 Ready: 1Early Clinical Feasibility: 1Pre-clinical/Proof-of-Concept: 1Phase 2 (next-gen): 1Clinical Study: 1Partnership/Development: 1Commercial & Development: 1Research-Use Only: 1IND filed: 1Validation/Clinical Study: 1Development/Late-Stage Testing: 1Pre-clinical/Early Clinical: 1Pre-clinical / Research: 1Research / Pre-clinical: 1Breakthrough Device: 1Commercial Roll-out: 1Advanced R&D: 1Continuous Certification: 1Phase 2a: 1Validated Instrument: 1Pre-validated/Validation Ongoing: 1Platform Expansion: 1Iterative Development: 1Commercial (Support Program): 1Preclinical (Phase 1 planned 2026): 1Discontinued: 1Partnership Stage: 1IND Accepted: 1NDA: 1IND: 1Phase 1/3: 1Filed/Phase III: 1Preclinical/Phase I: 1Multiple (I-III): 1Phase 3 / Marketed: 1Approved / Phase 3: 1ANDA Filed / Development: 1ANDA Filed/Approved: 1Regulatory (EU): 1Approved (EU): 1Marketed (ex-US): 1Pilot/Development: 1Discovery to Clinical: 1Preclinical Research: 1Preclinical to Commercial: 1Clinical Use: 1FDA 510(k) Submission: 1Research Use: 1Clinical Research / LDT: 1Phase 1/1b: 1Global Clinical Trial: 1Pre-market (NMPA approved 2025): 1NDA Filed: 1Phase 2 / Phase 2/3: 1Phase 1 / Phase 2: 1Preclinical / Phase 1: 1Approved / NDA Review: 1Phase 3 (planning): 1Phase 2 (imminent): 1Out-licensed: 1

Drug	Company	Indication	Phase	Status
Lectin-Fusion for LSDs (e.g., MPS I, Pompe)	SylamoreBio	Lysosomal Storage Disorders with CNS involvement	Pre-clinical	Active
Lectin-Fusion for Bone/Muscle Disorders	SylamoreBio	Musculoskeletal pathologies, abnormal bone growth	Pre-clinical	Active
RASTRUM™ 3D Pancreatic Cancer Model	Inventia Life Science	Pancreatic D	Pre‑clinical	Active
RASTRUM™ 3D Alzheimer’s Disease Model	Inventia Life Science	Alzheimer’s disease	Pre‑clinical	Active
RASTRUM™ 3D Tumor‑Immune Co‑culture Platform	Inventia Life Science	Immuno‑oncology	Pre‑clinical	Active
Dipraglurant (mGlu5 NAM)	Addex Therapeutics	Parkinson's Disease Levodopa-Induced Dyskinesia	Phase 2/3	Active
ADX71149 (mGlu2 PAM)	Addex Therapeutics	Epilepsy	Phase 2	Active (with Janssen)
GABAB PAM	Addex Therapeutics	Substance Use Disorder	Preclinical	Active
mGlu7 NAM	Addex Therapeutics	Anxiety and Fear-Related Disorders	Discovery/Preclinical	Active
EMu™ Brain Scanner	EMVision	Acute stroke diagnosis and monitoring	preclinical	Active
First Responder Brain Scanner	EMVision	Pre‑hospital stroke triage	preclinical	Active
Stem Cell Therapy for Blood Diseases	GIOSTAR	Sickle Cell Anemia, Leukemia, Lymphoma, Thalassemia	Not Disclosed	Active
Stem Cell Therapy for Type 1 Diabetes	GIOSTAR	Diabetes (Type 1)	Under Development	Active
Stem Cell Therapy for Neurodegenerative Diseases	GIOSTAR	Alzheimer’s, Parkinson’s, ALS, Multiple Sclerosis	Under Development	Active
Stem Cell Therapy for Autoimmune Diseases	GIOSTAR	Lupus, Crohn's, Vasculitis, Scleroderma	Under Development	Active
Takp-119	Akaal Pharma	Atopic dermatitis (pruritus)	Phase 2	Active
Oakp-11	Akaal Pharma	Autoimmune diseases; neuropathic pain	Phase 1	Active
Presendin™ (Exenatide)	Invex Therapeutics	Idiopathic Intracranial Hypertension (IIH)	Phase 2/3	Active
ARG-007	Argenica Therapeutics	Acute ischemic stroke, traumatic brain injury, hypoxic‑ischemic encephalopathy	Phase 2	Active
Remplir™	Orthocell	Peripheral nerve repair	Commercial	FDA cleared; EU/UK regulatory submissions pending
Autologous Tendon Therapy	Orthocell	Chronic tendon injuries	Clinical	Phase 2/3; >1,000 patients treated
OrthoACI™	Orthocell	Cartilage defects of knee and ankle	Commercial	Available in Australia
Turq-101	Turquoise Biotechnologies	Inflammatory Bowel Disease	Preclinical	Active
Turq-102	Turquoise Biotechnologies	Colon Cancer	Preclinical	Active
dl-3-n-Butylphthalide (NBP) Soft Capsules	cspc-pharmaceutical	Ischemic Stroke	Phase 3	Active (US trials with FDA orphan drug designation)
Benzonatate Soft Capsules	cspc-pharmaceutical	Cough Suppressant	Commercial	Marketed in US
Azithromycin Preparations	cspc-pharmaceutical	Bacterial Infections	Commercial	Marketed
Penem Preparations	cspc-pharmaceutical	Bacterial Infections	Commercial	Marketed
Various Penicillin/Cephalosporin Products	cspc-pharmaceutical	Bacterial Infections	Commercial	Marketed
ArtiBrain™	Tessara Therapeutics	Healthy human brain model	Preclinical	Active
ADBrain™	Tessara Therapeutics	Alzheimer's disease model	Preclinical	Active
UBX1325 (foselutoclax)	Unity Biotechnology	Diabetic Macular Edema (DME)	Phase 2b	Discontinued
UBX0105	Unity Biotechnology	Moderate-to-Severe Osteoarthritis of the Knee	Phase 2	Discontinued
UBX1967	Unity Biotechnology	Diabetic Macular Edema (DME), Wet AMD	Phase 1	Discontinued
RLS-2202	Patrys	Acute Delirium	Phase 1	Active
PAT-DX1	Patrys	Vasculitis / Inflammatory Disease	Preclinical	Active
PAT-DX3	Patrys	Vasculitis / Inflammatory Disease	Preclinical	Active
Deoxymab Oncology Candidate	Patrys	Solid Tumor Cancer	Preclinical	Active
NTI164	Neurotech International	Autism Spectrum Disorder	Phase 3	Active
MindMotion GO	MindMaze Therapeutics	Neurorehabilitation (e.g., Stroke, TBI)	Commercial	FDA Cleared / Deployed
MindPod	MindMaze Therapeutics	Motor & Cognitive Recovery	Commercial	Deployed
Izar	MindMaze Therapeutics	Hand Motor Function (Stroke, Parkinson’s, Alzheimer’s, TBI)	Commercial	Deployed
Physilog	MindMaze Therapeutics	Digital Motion Assessment & Biomarkers	Commercial	Deployed
Drug Development Program	MindMaze Therapeutics	Rare Diseases	Research	Early Development
U200 ESWL System	Wikkon	Kidney and Urinary Tract Stones	Commercial	FDA 510(k) Cleared (June 2025)
E300 ESWT System	Wikkon	Erectile Dysfunction	Commercial	Market Released
HK.SWT Series	Wikkon	Musculoskeletal Pain	Commercial	Market Released
Minder iCEM	Epiminder	Drug‑resistant epilepsy	Phase 2	Active
Alzheimer's Disease Diagnostic Reagents	Aptamer Group	Alzheimer's Disease Biomarker Detection	Development	Validated
Targeted siRNA Delivery (AstraZeneca Collab)	Aptamer Group	siRNA Delivery	Discovery/Development	Active